分化型甲状腺癌的个体化<sup>131</sup>I治疗

谭建; 谭建

doi:10.3760/cma.j.issn.1673-4114.2015.01.002

[1]

潘中允.临床实用核医学[M].北京: 人民卫生出版社, 2013.

[2]

黄刚.核医学与分子影像临床操作规范[M].北京: 人民卫生出版社, 2014.

[3]

Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2006, 16(2): 109-142.

[4]

中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2014版)[J].中华核医学与分子影像杂志, 2014, 34(4):264-278.

[5]

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19(11): 1167-1214.

[6]

中华医学会内分泌分会, 中华医学会外科分会, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床, 2012, 39(17):1249-1272.

[7]

Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 2012, 366(18): 1674-1685.

[8]

Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 2012, 366(18): 1663-1673.